Journal
BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY
Volume 35, Issue 3, Pages -Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.berh.2021.101687
Keywords
Systemic sclerosis; Scleroderma; Gastrointestinal; Microbiome; Microbiota
Categories
Funding
- National Medical Research Council, Singapore [NMRC/CSA-Inv/0022/2017]
Ask authors/readers for more resources
Systemic sclerosis (SSc) is a disease characterized by immune dysregulation, vasculopathy, and fibrosis of multiple organs, with the gastrointestinal (GI) tract being the most commonly affected organ. Recent studies have found unique microbial taxa alterations in the GI microbiome of SSc patients compared to healthy controls (HC), with potential associations with disease manifestations and severity.
Systemic sclerosis (SSc) is characterized by immune dysregulation, vasculopathy, and fibrosis of multiple organs. The gastrointestinal (GI) tract is the most common internal organ manifestation, which contributes to significant morbidity and mortality in patients with SSc. Emerging reports have identified unique microbial taxa alterations in the GI microbiome of patients with SSc as compared to healthy controls (HC). These taxa alterations include differences at the phyla (e.g., Bacteroidetes) and genera (e.g., Bacteroides, Clostridium, Faecalibacterium, and Lactobacillus) level. In addition, some genera have been associated with more severe GI symptoms (e.g., Prevotella and Akkermansia). This review summarizes the current evidence on factors influencing the GI microbiome, GI microbiome alterations in SSc as compared to HC, and in SSc subgroups according to disease manifestations. Current exploration in therapeutic interventions that target the GI microbiome is discussed. (C) 2021 Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available